Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]
Discontinued
Reference number: GID-TA10495
The Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation.
Please note that following on from advice received from the company the timelines for this appraisal have been revised and we now anticipate that the appraisal will begin during mid-June 2021 when we will write to you about how you can get involved.